Search - tctmd.com

Displaying 101 - 120 of 164

Sort: Relevancy | Date

News Conference News ESC 2019

New ‘Chronic Coronary Syndrome’ Guidelines Stress There’s Nothing Stable About CAD

Shelley Wood

August 31, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Conference News SCCT 2019

Doubling Down on SCOT-HEART: Mechanisms, Applicability, and Future Directions

Yael L. Maxwell

July 18, 2019

News Daily News

Registries Point to Lower Risk of Death With CABG vs PCI in Multivessel CAD

Michael O'Riordan

May 02, 2019

News Daily News

Zero CAC Reliably Excludes CAD Among Stable, Symptomatic Patients, but Experts Debate Its Need

Yael L. Maxwell

April 18, 2019

News Daily News

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

Michael O'Riordan

March 01, 2019

News Daily News

CT Angiography Bests Functional Testing in Diabetic Patients With Chest Pain: PROMISE

Michael O'Riordan

February 25, 2019

News Daily News

Atherosclerosis Features Differ Among Male Athletes From Different Sports

Todd Neale

February 18, 2019

News Daily News

No Excuses: Routine, High-Volume Exercise in Men Not Associated With Increased Mortality

Michael O'Riordan

February 01, 2019

News Daily News

Staged PCI or Complete Revasc? Physicians’ Practice Patterns Dictate Procedures

Michael O'Riordan

November 20, 2018

News Conference News AHA 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Michael O'Riordan

November 16, 2018

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

L.A. McKeown

November 15, 2018

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Conference News AHA 2018

New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening

Michael O'Riordan

November 10, 2018

News Daily News

SORT-OUT IX: Statistical Mix-up Turns Trial’s Primary Endpoint Around

Michael O'Riordan

November 06, 2018

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

News Daily News

Long-term Risk Factor Control Linked to Survival in COURAGE Substudy

Yael L. Maxwell

October 30, 2018

News Conference News TCT 2018

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

Michael O'Riordan

October 02, 2018

Advertisement

New ‘Chronic Coronary Syndrome’ Guidelines Stress There’s Nothing Stable About CAD

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Doubling Down on SCOT-HEART: Mechanisms, Applicability, and Future Directions

Registries Point to Lower Risk of Death With CABG vs PCI in Multivessel CAD

Zero CAC Reliably Excludes CAD Among Stable, Symptomatic Patients, but Experts Debate Its Need

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

CT Angiography Bests Functional Testing in Diabetic Patients With Chest Pain: PROMISE

Atherosclerosis Features Differ Among Male Athletes From Different Sports

No Excuses: Routine, High-Volume Exercise in Men Not Associated With Increased Mortality

Staged PCI or Complete Revasc? Physicians’ Practice Patterns Dictate Procedures

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening

SORT-OUT IX: Statistical Mix-up Turns Trial’s Primary Endpoint Around

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Long-term Risk Factor Control Linked to Survival in COURAGE Substudy

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content